| Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: a mechanistic model and tool for regimen and dose optimization N Strydom, SV Gupta, WS Fox, LE Via, H Bang, M Lee, S Eum, TS Shim, ... PLoS medicine 16 (4), e1002773, 2019 | 161 | 2019 |
| New paradigm for translational modeling to predict long‐term tuberculosis treatment response IH Bartelink, N Zhang, RJ Keizer, N Strydom, PJ Converse, KE Dooley, ... Clinical and translational science 10 (5), 366-379, 2017 | 39 | 2017 |
| Development of new tuberculosis drugs: translation to regimen composition for drug-sensitive and multidrug-resistant tuberculosis JP Ernest, N Strydom, Q Wang, N Zhang, E Nuermberger, V Dartois, ... Annual review of pharmacology and toxicology 61, 495-516, 2021 | 30 | 2021 |
| Antimalarial benzoheterocyclic 4-aminoquinolines: structure–activity relationship, in vivo evaluation, mechanistic and bioactivation studies DSB Ongarora, N Strydom, K Wicht, M Njoroge, L Wiesner, TJ Egan, ... Bioorganic & medicinal chemistry 23 (17), 5419-5432, 2015 | 29 | 2015 |
| Mathematical model and tool to explore shorter multi-drug therapy options for active pulmonary tuberculosis J Fors, N Strydom, WS Fox, RJ Keizer, RM Savic PLOS Computational Biology 16 (8), e1008107, 2020 | 24 | 2020 |
| Mechanistic modeling of Mycobacterium tuberculosis infection in murine models for drug and vaccine efficacy studies N Zhang, N Strydom, S Tyagi, H Soni, R Tasneen, EL Nuermberger, ... Antimicrobial agents and chemotherapy 64 (3), 10.1128/aac. 01727-19, 2020 | 17 | 2020 |
| Pharmacokinetics and organ distribution of C-3 alkyl esters as potential antimycobacterial prodrugs of fusidic acid N Strydom, G Kaur, GA Dziwornu, J Okombo, L Wiesner, K Chibale ACS infectious diseases 6 (3), 459-466, 2020 | 15 | 2020 |
| Emerging therapeutics, technologies, and drug development strategies to address patient nonadherence and improve tuberculosis treatment M Garcia-Cremades, BP Solans, N Strydom, B Vrijens, GC Pillai, ... Annual Review of Pharmacology and Toxicology 62, 197-210, 2022 | 14 | 2022 |
| Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis JP Ernest, J Sarathy, N Wang, F Kaya, MD Zimmerman, N Strydom, ... Antimicrobial agents and chemotherapy 65 (10), 10.1128/aac. 00506-21, 2021 | 14 | 2021 |
| Model-based efficacy and toxicity comparisons of moxifloxacin for multidrug-resistant tuberculosis HY Yun, V Chang, KK Radtke, Q Wang, N Strydom, MJ Chang, RM Savic Open forum infectious diseases 9 (3), ofab660, 2022 | 8 | 2022 |
| Examining nonadherence in the treatment of tuberculosis: The patterns that lead to failure WS Fox, N Strydom, MZ Imperial, L Jarlsberg, RM Savic British Journal of Clinical Pharmacology 89 (7), 1965-1977, 2023 | 6 | 2023 |
| CPT: Pharmacometrics & Systems Pharmacology–inception, maturation, and future vision KR Yeo, S Hennig, S Krishnaswami, N Strydom, VS Ayyar, J French, ... CPT: Pharmacometrics & Systems Pharmacology 10 (7), 649, 2021 | 6 | 2021 |
| New paradigm for translational modeling to predict long-term tuberculosis treatment response. Clin Transl Sci 10: 366–379 IH Bartelink, N Zhang, RJ Keizer, N Strydom, PJ Converse, KE Dooley, ... | 6 | 2017 |
| Prothionamide dose optimization using population pharmacokinetics for multidrug-resistant tuberculosis patients H Yun, MJ Chang, H Jung, V Chang, Q Wang, N Strydom, YR Yoon, ... Antimicrobial agents and chemotherapy 66 (9), e01893-21, 2022 | 4 | 2022 |
| Drug concentration at the site of disease in children with pulmonary tuberculosis E Lopez-Varela, AA Abulfathi, N Strydom, P Goussard, AC Van Wyk, ... Journal of Antimicrobial Chemotherapy 77 (6), 1710-1719, 2022 | 4 | 2022 |
| LBA10 Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study F Pietrantonio, L Salvatore, T Esaki, DP Modest, D Paez, J Taieb, ... Annals of Oncology 34, S1266, 2023 | 1 | 2023 |
| Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs JP Ernest, JJN Goh, N Strydom, Q Wang, RC van Wijk, N Zhang, ... European Respiratory Journal 62 (2), 2023 | 1 | 2023 |
| Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure … M Garcia-Cremades, CW Hendrix, P Jayachandran, N Strydom, ... Pharmaceutics 14 (9), 1801, 2022 | 1 | 2022 |
| LIMITED PENETRATION AND EFFICACY OF AMINOGLYCOSIDES IN LESIONS OF TUBERCULOSIS: A TRANSLATIONAL SITE-OF-ACTION PKPD MODELING STUDY. J Ernest, N Strydom, J Sarathy, M Zimmerman, V Dartois, R Savic CLINICAL PHARMACOLOGY & THERAPEUTICS 109, S28-S28, 2021 | 1 | 2021 |
| PREDICTING THE EARLY BACTERICIDAL ACTIVITY (EBA) OF TUBERCULOSIS (TB) DRUGS FOR THE PHASE IIA FIRST-IN-PATIENTS STUDIES. N Zhang, N Strydom, Q Wang, J Ernest, E Nuermberger, R Savic CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S83-S83, 2020 | 1 | 2020 |
